3,950 Shares in Cencora, Inc. (NYSE:COR) Purchased by Swmg LLC

Swmg LLC bought a new position in shares of Cencora, Inc. (NYSE:COR - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 3,950 shares of the company's stock, valued at approximately $987,000.

Several other hedge funds and other institutional investors have also bought and sold shares of COR. CWM LLC increased its stake in shares of Cencora by 4.5% in the 2nd quarter. CWM LLC now owns 11,898 shares of the company's stock valued at $2,681,000 after acquiring an additional 509 shares in the last quarter. Valeo Financial Advisors LLC raised its stake in Cencora by 3.4% during the 2nd quarter. Valeo Financial Advisors LLC now owns 1,566 shares of the company's stock worth $353,000 after buying an additional 51 shares during the period. SG Americas Securities LLC boosted its holdings in Cencora by 39.9% in the second quarter. SG Americas Securities LLC now owns 34,478 shares of the company's stock worth $7,768,000 after acquiring an additional 9,840 shares in the last quarter. Gateway Investment Advisers LLC grew its stake in Cencora by 15.7% in the second quarter. Gateway Investment Advisers LLC now owns 4,024 shares of the company's stock valued at $907,000 after acquiring an additional 546 shares during the period. Finally, MJP Associates Inc. ADV increased its holdings in shares of Cencora by 3.2% during the second quarter. MJP Associates Inc. ADV now owns 2,372 shares of the company's stock valued at $534,000 after acquiring an additional 73 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company's stock.

Cencora Stock Performance

Cencora stock traded down $4.03 during trading on Thursday, hitting $244.31. The stock had a trading volume of 1,325,823 shares, compared to its average volume of 1,390,713. The stock's 50 day moving average is $236.34 and its two-hundred day moving average is $233.11. Cencora, Inc. has a 1 year low of $195.83 and a 1 year high of $253.27. The stock has a market cap of $48.14 billion, a price-to-earnings ratio of 33.09, a price-to-earnings-growth ratio of 1.66 and a beta of 0.45. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Investors of record on Friday, November 15th were issued a $0.55 dividend. The ex-dividend date was Friday, November 15th. This represents a $2.20 annualized dividend and a yield of 0.90%. This is a positive change from Cencora's previous quarterly dividend of $0.51. Cencora's dividend payout ratio (DPR) is 29.29%.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Barclays boosted their price target on shares of Cencora from $263.00 to $290.00 and gave the company an "overweight" rating in a research note on Thursday, November 7th. Evercore ISI increased their price objective on Cencora from $250.00 to $285.00 and gave the stock an "outperform" rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. lifted their target price on Cencora from $280.00 to $287.00 and gave the company an "overweight" rating in a research report on Wednesday, August 21st. Robert W. Baird increased their price target on Cencora from $287.00 to $292.00 and gave the company an "outperform" rating in a research report on Thursday, November 7th. Finally, Leerink Partners reduced their target price on shares of Cencora from $277.00 to $275.00 and set an "outperform" rating for the company in a research note on Monday, October 7th. Two analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, Cencora currently has a consensus rating of "Moderate Buy" and an average price target of $276.80.

Insider Buying and Selling at Cencora

In other Cencora news, Chairman Steven H. Collis sold 50,000 shares of Cencora stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the completion of the transaction, the chairman now owns 326,557 shares of the company's stock, valued at $79,670,111.29. The trade was a 13.28 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 93,018 shares of company stock valued at $22,478,942 over the last three months. 15.80% of the stock is currently owned by insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.